BeiGene | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Beigene Study ID

BGB-A317-A445-201

ClinicalTrials.gov ID

NCT05661955

China Drug Trials ID

CTR20223270

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents